Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljad396 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Wanlong Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology. Hauptthemen laut MEDLINE: Dermatomyositis, Janus Kinase Inhibitors, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
In this retrospective case series, off-label use of Janus kinase inhibitor rapidly and significantly ameliorated the active cutaneous disease in all five glucocorticoid-resistant patients with cancer-associated dermatomyositis who had anti-transcription intermediary factor 1-γ antibodies, showing a promising steroid-sparing effect and a generally well-tolerated safety profile beyond 1-year follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology.
- Jiading Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Wanlong Wu, Kaiwen Wang, Shuang Ye
Zitieren
APA
Wu, W., Chen, J., Zhu, L., Sha, Y., Wang, K., Zhao, J., Ye, C., & Ye, S. (2024). Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad396
Vancouver
Wu W, Chen J, Zhu L, Sha Y, Wang K, Zhao J, et al. Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad396
BibTeX
@article{Wu2024,
author = {Wu, Wanlong and Chen, Jinju and Zhu, Linling and Sha, Yaping and Wang, Kaiwen and Zhao, Jiangfeng and Ye, Chunhua and Ye, Shuang},
title = {Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljad396}
}
EUVIMED